Breaking News Instant updates and real-time market news.

WM

Waste Management

$82.60

(0.00%)

, PG

Procter & Gamble

$80.68

(0.00%)

09:40
02/15/18
02/15
09:40
02/15/18
09:40

Unusually active option classes on open February 15th

Unusual total active option classes on open include: Waste Management (WM), Procter & Gamble (PG), Altria Group (MO), PepsiCo (PEP), Applied Materials (AMAT), Honeywell (HON), United Technologies (UTX), TripAdvisor (TRIP), Teva (TEVA), and Barrick Gold (ABX).

WM

Waste Management

$82.60

(0.00%)

PG

Procter & Gamble

$80.68

(0.00%)

MO

Altria Group

$65.18

(0.00%)

PEP

PepsiCo

$109.11

-3.03 (-2.70%)

AMAT

Applied Materials

$51.96

2.41 (4.86%)

HON

Honeywell

$150.38

(0.00%)

UTX

United Technologies

$126.00

(0.00%)

TRIP

TripAdvisor

$40.72

0.84 (2.11%)

TEVA

Teva

$19.33

(0.00%)

ABX

Barrick Gold

$13.65

(0.00%)

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 16

    Feb

  • 19

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 26

    Feb

  • 07

    Mar

  • 30

    May

  • 25

    Jun

WM Waste Management
$82.60

(0.00%)

01/03/18
MACQ
01/03/18
UPGRADE
Target $114
MACQ
Outperform
Waste Management upgraded to Outperform on strong cash flow at Macquarie
As previously reported, Macquarie upgraded Waste Management to Outperform from Neutral and raised its price target to $114 from $79. Analyst Hamzah Mazari expects a structurally higher free cash flow profile going forward driven by sustainable working capital improvement metrics, sees significant self help opportunities to bring customer churn down, higher than expected structural cash tax savings, and views valuation as attractive versus peers.
01/03/18
MACQ
01/03/18
UPGRADE
MACQ
Outperform
Waste Management upgraded to Outperform from Neutral at Macquarie
12/11/17
12/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. U.S. Steel (X) upgraded to Hold from Sell at Axiom with analyst Gordon Johnson saying he believes protectionism from the Trump administration and positive seasonality could create a "more optimistic tone" in the near-term. 2. Waste Management (WM) upgraded to Buy from Hold at Stifel with analyst Michael Hoffman saying he believes the company can embrace technology to improve customer experience, lower turnover, support better pricing, and improve productivity. 3. Air Products (APD) upgraded to Buy from Hold at Jefferies with analyst Laurence Alexander saying he believes the industrial gases are positioned for a "classic late-cycle trade" amid improving industrial demand and a turn in the capex cycle. 4. DaVita (DVA) upgraded to Buy from Neutral at Citi with analyst Patrick Wood saying the sale of the company's DMG unit has resulted in an "unusual situation" where almost 40% of DaVita's current market capitalization is cash. 5. First Solar (FSLR) upgraded to Outperform from Neutral at Baird with analyst Ben Kallo citing its strong pipeline and balance sheet and continued cost and efficiency improvements. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/17
12/11/17
UPGRADE
Target $95

Buy
Waste Management upgraded to Buy, added to Select List at Stifel
As previously reported, Stifel analyst Michael Hoffman upgraded Waste Management to Buy from Hold, saying he believes the company can embrace technology to improve customer experience, lower turnover, support better pricing, and improve productivity. Hoffman, who also added the stock to the Stifel Analyst Select List and raised his price target on the shares to $95 from $80, also cited the company's organic growth, better free cash flow outlook and benefits from tax reform.
PG Procter & Gamble
$80.68

(0.00%)

12/27/17
JEFF
12/27/17
NO CHANGE
JEFF
Nielsen shows improved two-week sales trends, says Jefferies
Jefferies analyst Kevin Grundy says two-week sales growth in U.S. Nielsen channels improved sequentially for key home and personal care companies Colgate-Palmolive (CL), Church & Dwight (CHD) and Clorox (CLX), as well as beverage companies Monster Beverage (MNST), Coca-Cola (KO) and Dr Pepper Snapple (DPS). While overall growth remains tepid, sequential improvement in December for consumer spending, including staples, has been more upbeat, Grundy tells investors in a research note titled "Party Like It's 1999? Not Quite, But US Nielsen HPC/Bevs 2-Week Data Improves." The analyst favors shares of Church & Dwight, Procter & Gamble (PG), Dr Pepper and Monster.
01/16/18
GSCO
01/16/18
UPGRADE
Target $88
GSCO
Neutral
Procter & Gamble upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jason English upgraded Procter & Gamble to Neutral and raised his price target for the shares to $88 from $83. The analyst no longer sees enough downside to estimates to drive material underperformance for the stock. he admits his expectation of a negative estimate revision cycle has failed to materialize.
01/16/18
01/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Buy from Neutral at Nomura Instinet with analyst Romit Shah saying with Broadcom's (AVGO) hostile takeover attempt now analogous to a "gun to the head," Qualcomm management is likely to more aggressively focus on driving shareholder value in order to remain a standalone franchise. 2. Twitter (TWTR) upgraded to Buy from Sell at Aegis with analyst Victor Anthony saying he believes 2018 will be an inflection point in owned and operated advertising for Twitter and he sees a return to double-digit growth in that area in 2019. 3. Procter & Gamble (PG) upgraded to Neutral from Sell at Goldman Sachs with analyst Jason English saying he no longer sees enough downside to estimates to drive material underperformance for the stock. 4. Northrop Grumman (NOC) and Curtiss-Wright (CW) were upgraded to Outperform from Market Perform at Wells Fargo. 5. Ciena (CIEN) was upgraded to Buy from Neutral at Goldman Sachs, while Adtran (ADTN) was upgraded to Neutral from Sell. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/17
DBAB
12/13/17
INITIATION
Target $101
DBAB
Buy
Procter & Gamble initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Steve Powers started Procter & Gamble with a Buy rating and $101 price target. The company is well positioned after "finally" catching up with market realities," the analyst contends. He views the risk/reward as attractive at current share levels.
MO Altria Group
$65.18

(0.00%)

01/19/18
JEFF
01/19/18
UPGRADE
Target $81
JEFF
Buy
Altria Group upgraded to Buy from Hold at Jefferies
Jefferies analyst Owen Bennett upgraded Altria Group to Buy saying he's bullish on Tobacco for fiscal 2018. The analyst sees returns driven by "solid" EBITDA, easing regulatory concerns and benefits from tax reform. He also sees the possibility of large-scale acquisitions adding to the upside. The analyst upped his price target for Altria Group shares to $81.
01/19/18
JEFF
01/19/18
UPGRADE
Target $124
JEFF
Buy
Philip Morris upgraded to Buy from Hold at Jefferies
Jefferies analyst Owen Bennett upgraded Philip Morris to Buy saying he's bullish on Tobacco for fiscal 2018. The analyst sees returns driven by "solid" EBITDA, easing regulatory concerns and benefits from tax reform. He also sees the possibility of large-scale acquisitions adding to the upside. The analyst upped his price target for Philip Morris shares to $124. Bennett this morning also upgraded Altria Group (MO) to Buy. British American Tobacco (BTI) remains his top pick, followed by Altria, then Philip Morris.
01/19/18
01/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Outperform from Neutral at Wedbush analyst Christopher Svezia saying the brand's new footwear styles are "notably higher" versus a year ago while comparisons are easing, particularly around key categories like basketball. 2. Abercrombie & Fitch (ANF) upgraded to Buy from Hold at Argus with analyst John Eade saying the stock has "fallen out of favor" with its core market, but the turnaround strategy implemented by the new CEO, along with the hiring of a Chief Marketing Officer, has produced two consecutive quarter of earnings beats. 3. Chipotle (CMG) upgraded to Market Perform from Underperform at Raymond James with analyst Brian Vaccaro citing fair valuation and no longer sees downside risk given management's decision to take a third and final round of menu price increases and stabilizing industry demand trends. 4. Foot Locker (FL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Kelly Chen saying the worst of the athletic industry's issues have passed. 5. Philip Morris (PM) and Altria Group (MO) were upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/26/18
JEFF
01/26/18
NO CHANGE
JEFF
Buy
Jefferies sees 'big opportunity' in British American Tobacco after selloff
Jefferies analyst Owen Bennett sees a "big opportunity" in shares of British American Tobacco (BTI) following yesterday's selloff. There is a "very strange disconnect here," Bennett tells investors in a research note. The 3.5% pullback doesn't make sense, he adds. He believes that if the market thinks Philip Morris' (PM) IQOS won't get approved, then it is a positive for British American Tobacco. The analyst thinks the selloff can only be explained by holders assuming a Premarket Tobacco Application for IQOS will be approved. Such an approval will likely create support for Philip Morris and Altria Group (MO), Bennett argues. Following conversations in the U.S., the analyst sees a "complete lack of knowledge" around where British American Tobacco stands with heated tobacco approvals. Bennett has Buy ratings on all three stocks.
PEP PepsiCo
$109.11

-3.03 (-2.70%)

02/14/18
EVER
02/14/18
DOWNGRADE
EVER
In Line
PepsiCo downgraded to In Line at Evercore ISI on NAB issues
As reported earlier, Evercore ISI analyst Robert Ottenstein downgraded PepsiCo to In Line from Outperform. The analyst says that while the company's dividend increase is "important and positive", he no longer expects the company to outperform in the beverage sector amid an "array of issues" at North America Beverage segment limiting upside performance. Ottenstein also points to rising commodity prices and expectations of the company to increase marketing expenses in NAB if results do not materialize. potentially putting downward pressure on the second half of 2018 earnings.
02/14/18
EVER
02/14/18
DOWNGRADE
EVER
In Line
PepsiCo downgraded to In Line from Outperform at Evercore ISI
02/14/18
RHCO
02/14/18
NO CHANGE
Target $115
RHCO
Hold
PepsiCo price target lowered to $115 from $125 at SunTrust
SunTrust analyst William Chappell lowered his price target on PepsiCo to $115 from $125, saying it is surprising that investors are giving the company a pass on its decision to reinvest a majority of its tax savings back into the business. The analyst adds that while PepsiCo's North America Beverage segment organic sales improved sequentially to -3% from -5%, they remain below the multi-year track record of low-single-digit growth. While the company has plans for product innovation and brand building, the analyst contends that the flat growth remains a concern. Chappell keeps his Hold rating on PepsiCo.
02/14/18
02/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to In Line from Outperform at Evercore ISI with analyst Robert Ottenstein saying that while the company's dividend increase is "important and positive," he no longer expects the company to outperform in the beverage sector amid an "array of issues" at North America Beverage segment limiting upside performance. 2. Spark Therapeutics (ONCE) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying he remains optimistic about the long-term outlook for the company, but notes the shares are now within 10% of his price target following the recent rally. 3. Chimerix (CMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying with base-case timing for the AdAPT data well over a year away, the shares will underperform over the near term. 4. Avis Budget (CAR) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying he believes transitory benefits from Hurricane recovery demand are waning, and headwinds from reduced residual values, higher interest rates, continued competition, and increased SG&A expenses will pressure Avis' earnings outlook. 5. Lexicon (LXRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying the Xermelo launch remains slow, and consensus estimates of $55M and $99M for 2018 and 2019 are too high. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AMAT Applied Materials
$51.96

2.41 (4.86%)

02/15/18
STFL
02/15/18
NO CHANGE
Target $71
STFL
Buy
Applied Materials price target raised to $71 from $66 at Stifel
Stifel analyst Patrick Ho noted that Applied Materials' Q1 results topped his and consensus expectations and the company "exuded a very positive tone" on 2018 in its earnings report commentary. Following the earnings call, he has raised his estimates for Applied Materials and increased his price target on the stock to $71. Ho keeps a Buy rating on Applied Materials, which he calls the top stock in his coverage.
02/15/18
COWN
02/15/18
NO CHANGE
COWN
Outperform
Applied Materials commentary positive for wafer fab companies, says Cowen
Cowen analyst Karl Ackerman said Applied Materials' (AMAT) commentary following its solid Q1 results is positive for wafer fabrication companies Ichor Holdings (ICHR) and Ultra Clean (UCTT). The commentary indicated a healthy wafer fab equipment environment through 2019, suggesting the strong selloff amid fears of a material deceleration in equipment spending is overblown. Ackerman raised his estimates and reiterated his Outperform rating on both Ichor Holdings and Ultra Clean shares.
02/15/18
KEYB
02/15/18
NO CHANGE
Target $74
KEYB
Overweight
Applied Materials price target raised to $74 from $67 at KeyBanc
KeyBanc analyst Weston Twigg raised his price target for Applied Materials to $74 from $67 after the company posted another beat and raise amid very high demand for semiconductor and display equipment. The analyst reiterates an Overweight rating on the shares.
02/15/18
DBAB
02/15/18
NO CHANGE
Target $70
DBAB
Buy
Applied Materials price target raised to $70 from $65 at Deutsche Bank
Deutsche Bank analyst Sidney Ho raised his price target for Applied Materials to $70 saying the company last night delivered a beat and raise as he expected. While management did not provide a point estimate for 2018 WFE, their comment that a WFE of $50B or more in the near term is consistent with peers, Ho tells investors in a post-earnings research note. He raised his estimates for Applied Materials and keeps a Buy rating on the shares.
HON Honeywell
$150.38

(0.00%)

01/03/18
RBCM
01/03/18
DOWNGRADE
Target $158
RBCM
Sector Perform
Honeywell downgraded to Sector Perform at RBC Capital on valuation
As reported earlier, RBC Capital analyst Deane Dray downgraded Honeywell to Sector Perform from Outperform and lowered his price target to $158 from $163. Dray says the stock is likely to "take a breather" this year after a solid run in 2017, adding that despite the potential margin upside, the positive catalysts of "Turbo/Homes spin announcements and CEO transition" have played out. Dray adds that his enthusiasm for Honeywell is less pronounced because of its "60% short-cycle exposure".
01/03/18
01/03/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Harley-Davidson (HOG) downgraded to Underperform from Neutral at Longbow with analyst David MacGregor saying channel checks in the fourth quarter revealed that Harley's U.S. retail sales are trending down 5%-7% with U.S. shipments expected to be down at least 20%. 2. TJX (TJX) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying Marmaxx has simply become too big to generate share gains similar to years past. 3. Honeywell (HON) downgraded to Sector Perform from Outperform at RBC Capital with analyst Deane Dray saying the stock is likely to "take a breather" this year after a solid run in 2017, adding that despite the potential margin upside, the positive catalysts of "Turbo/Homes spin announcements and CEO transition" have played out. 4. Pinnacle West (PNW) downgraded to Underperform from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith saying valuation is priced at the "pinnacle" and sees risks that a -$1.3B CapEx budget still results in earnings closer to -5% on a net basis, and potential downside to Street estimates of between 5c-10c. 5. Charles Schwab (SCHW) downgraded to Market Perform from Outperform at JMP Securities with analyst Devin Ryan saying he now views its valuation as more adequately reflecting the current risk and reward following the stock's recent outperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/22/18
UBSW
01/22/18
INITIATION
Target $182
UBSW
Buy
Honeywell initiated with a Buy at UBS
UBS initiated Honeywell with a Buy and $182 price target.
02/15/18
LEHM
02/15/18
INITIATION
Target $170
LEHM
Overweight
Honeywell initiated with an Overweight at Barclays
Barclays analyst Julian Mitchell started Honeywell with an Overweight rating and $170 price target. The analyst initiated 24 Multi-Industry companies with a Neutral sector view.
UTX United Technologies
$126.00

(0.00%)

02/09/18
ARGS
02/09/18
UPGRADE
Target $150
ARGS
Buy
United Technologies upgraded to Buy at Argus on infrastructure spending prospect
As reported earlier, Argus analyst John Eade upgraded United Technologies to Buy from Hold with a price target of $150. Eade says the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. The analyst adds that the stock has outperformed the market over the past quarter and should see more upside ahead given the optimism over reduced corporate tax rates and prospects for increased infrastructure spending. Eade says his valuation gives him a price target of $140 on comparative multiple analysis and $160 based on his dividend discount model.
02/09/18
02/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Sector Perform from Underperform at RBC Capital with analyst Mark Mahaney saying the fourth quarter revenue and EBITDA were materially better than expected, and while MAU's were below consensus, DAU's grew for the first time at a double-digit rate. 2. iRobot (IRBT) upgraded to Outperform from Market Perform at Raymond James with analyst Mark Strouse saying he sees a more balanced risk/reward following the recent pullback in the shares. 3. Regeneron (REGN) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney noting its selloff since last year and believes its valuation has reached a point where the selloff is overdone. 4. Teva (TEVA) upgraded to Sector Perform from Underperform at RBC Capital with analyst Randall Stanicky saying the 11% sell-off in the stock price following the company's guidance update has removed the debate around 2018 EBITDA target and sees limited downside from the current levels. 5. United Technologies (UTX) upgraded to Buy from Hold at Argus with analyst John Eade saying the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/15/18
LEHM
02/15/18
INITIATION
Target $157
LEHM
Overweight
United Technologies initiated with an Overweight at Barclays
Barclays analyst Julian Mitchell started United Technologies with an Overweight rating and $157 price target. The analyst initiated 24 Multi-Industry companies with a Neutral sector view.
02/09/18
ARGS
02/09/18
UPGRADE
ARGS
Buy
United Technologies upgraded to Buy from Hold at Argus
TRIP TripAdvisor
$40.72

0.84 (2.11%)

01/02/18
BOFA
01/02/18
NO CHANGE
BOFA
BofA/Merrill's Top 10 US Ideas for Q1 2018
BofA/Merrill named its Top 10 Ideas for Q1 2018. They are Buy rated AMD (AMD), Disney (DIS), Exact Sciences (EXAS), Exelon (EXC), lululemon (LULU), PayPal (PYPL), United Rentals (URI), and Walmart (WMT), and Underperform rated L Brands (LB) and TripAdvisor (TRIP).
02/15/18
PIPR
02/15/18
NO CHANGE
Target $47
PIPR
Neutral
TripAdvisor price target raised to $47 from $40 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for TripAdvisor to $47 saying the company last night reported "strong" results with revenue and EBITDA above consensus. TripAdvisor guided to flat year-over-year EBITDA, which is favorable when compared to consensus at down 5.5%, Olson tells investors in a post-earnings research note. He maintains a Neutral rating on the shares.
02/15/18
JEFF
02/15/18
NO CHANGE
Target $27
JEFF
Underperform
TripAdvisor core business is declining, valuation looks rich, says Jefferies
In a post-earnings research note titled "Stay Clear of This Trip," Jefferies analyst Brent Thill says TripAdvisor last night reported a mixed quarter with revenue and adjusted EBITDA above consensus and operating earnings short of expectations on higher taxes. The analyst sees "much better alternatives" among the online travel agencies with TripAdvisor's core business declining and its stock trading at 15 times 2018 EBITDA estimates. Thill says the valuation "looks rich" and keeps an Underperform rating on TripAdvisor with a $27 price target.
01/05/18
SBSH
01/05/18
NO CHANGE
Target $1400
SBSH
Buy
Citi names Amazon top Internet pick for 2018, ups target to $1,400
Citi analyst Mark May remains bullish on the consumer Internet sector, especially over the near term. The analyst believes a "positive, tax reform fueled, business climate" should benefit the end-markets of the companies in the space. After outperformance in 2017, however, he recommends being more selective in 2018. Amazon.com (AMZN) moves up a spot to become his top-ranked pick for 2018. May sees the combination of greater than 30% sales growth, margin expansion and the current valuation as a "compelling mix." He raised his price target for Amazon shares to $1,400 from $1,250. May's most- to least-favored stocks under coverage, in order, are: Amazon, Expedia (EXPE), Facebook (FB), Priceline (PCLN), Alphabet (GOOGL), eBay (EBAY), Yelp (YELP), Twitter (TWTR), TripAdvisor (TRIP), Netflix (NFLX), GrubHub (GRUB), GoDaddy (GDDY), Despegar.com (DESP), trivago (TRVG), LendingClub (LC), Wayfair (W), Snap (SNAP), Zillow (ZG), Blue Apron (APRN) and Roku (ROKU), which he downgraded this morning to Sell.
TEVA Teva
$19.33

(0.00%)

02/12/18
02/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nasdaq (NDAQ) upgraded to Outperform from Market Perform at Wells Fargo by analyst Christopher Harris, who said the company is at an inflection point where both its trading and non-trading segments will begin to generate faster growth. He sees a "pathway to much higher profit margin" over the next two years and believes the stock is "relatively inexpensive" at a discount to the S&P 500 Index. 2. Teva (TEVA) upgraded to Outperform from Neutral at Credit Suisse by analyst Vamil Divan. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer. 3. Cisco Systems (CSCO) upgraded to Buy from Neutral at Nomura Instinet by analyst Jeffrey Kvaal to reflect the webscale uptick and believes tax reform and the company's recurring revenue transition provide downside protection. Kvaal believes the recent pullback in Cisco shares provides a buying opportunity. 4. Tallgrass Energy Partners (TEP) upgraded to Overweight from Equal Weight at Barclays by analyst Christine Cho, who lowered her price target to $43 from $50. The analyst said her analysis suggests a Tallgrass Energy GP (TEGP) acquisition of Tallgrass Energy Partners is the most likely scenario. She valued Tallgrass Energy Partner at $43 in this scenario. 5. VF Corp (VFC) upgraded to Buy from hold at Stifel by analyst Jim Duffy, who sees fiscal 2019 consensus estimates rising throughout the year due to fundamental strength, environmental factors, and currency. Duffy believes VF shares can sustain the premium multiple for the "foreseeable future." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
FBCO
02/12/18
UPGRADE
Target $23
FBCO
Outperform
Credit Suisse upgrades Teva to Outperform amid execution on restructuring
Credit Suisse analyst Vamil Divan upgraded Teva Pharmaceutical to Outperform from Neutral and raised his price target for the shares to $23 from $20. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer.
02/11/18
FBCO
02/11/18
UPGRADE
FBCO
Outperform
Teva upgraded to Outperform from Neutral at Credit Suisse
02/13/18
WELS
02/13/18
NO CHANGE
WELS
Teva generic comes earlier than expected, says Wells Fargo
Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.
ABX Barrick Gold
$13.65

(0.00%)

11/30/17
SBSH
11/30/17
DOWNGRADE
Target $13
SBSH
Sell
Barrick Gold downgraded to Sell from Buy at Citi
Citi analyst Alexander Hacking double downgraded Barrick Gold (ABX) to Sell from Buy and cut his price target for the shares to $13 from $20. The analyst cites the company's operating issues and potential for an upcoming reinvestment cycle. He remains "neutral to cautious" on the gold sector heading into 2018. Hacking this morning also upgraded Goldcorp (GG) to Buy and Agnico Eagle (AEM) to Neutral.
11/01/17
RBCM
11/01/17
DOWNGRADE
Target $18
RBCM
Sector Perform
Barrick Gold cut to Sector Perform at RBC Capital on production uncertainties
As noted earlier, RBC Capital analyst Stephen Walker cut Barrick Gold to Sector Perform from Outperform and also lowered his price target to $18 from $21. Walker says the market has now priced in the company's deleveraging and cost-reduction efforts, noting investor focus now shifts to uncertainties around JV partnerships and the resolution regarding Acacia operations with Tanzania government. Capital allocation toward new mine development will also make share buybacks and dividend increases unlikely, the analyst writes in his research note.
11/01/17
RBCM
11/01/17
DOWNGRADE
RBCM
Sector Perform
Barrick Gold downgraded to Sector Perform from Outperform at RBC Capital
10/26/17
FBCO
10/26/17
DOWNGRADE
Target $19
FBCO
Neutral
Barrick Gold downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Anita Soni downgraded Barrick Gold to Neutral and lowered her price target for the shares to $19 from $22. With the majority of asset sales and balance sheet repair now completed, investor focus will shift to the "weaker operational results" in 2017 and value loss at Acacia, Soni tells investors in a research note following Barrick's Q3 results.

TODAY'S FREE FLY STORIES

FII

Federated Investors

$24.65

-0.02 (-0.08%)

21:40
12/16/18
12/16
21:40
12/16/18
21:40
Initiation
Federated Investors initiated at Gabelli »

Federated Investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIII

G-III Apparel

$28.68

-0.29 (-1.00%)

21:37
12/16/18
12/16
21:37
12/16/18
21:37
Upgrade
G-III Apparel rating change at Stifel »

G-III Apparel upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

21:34
12/16/18
12/16
21:34
12/16/18
21:34
Upgrade
Calyxt rating change at Goldman Sachs »

Goldman upgrades Calyxt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLXT

Calyxt

$9.88

0.4 (4.22%)

20:23
12/16/18
12/16
20:23
12/16/18
20:23
Upgrade
Calyxt rating change at Goldman Sachs »

Calyxt upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

, EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

20:08
12/16/18
12/16
20:08
12/16/18
20:08
Recommendations
Crestwood Equity, EQT Midstream Partners analyst commentary at Goldman Sachs »

Goldman upgrades…

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$131.02

-2.26 (-1.70%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Downgrade
Illinois Tool Works rating change at Deutsche Bank »

Illinois Tool Works…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$118.36

0.46 (0.39%)

19:57
12/16/18
12/16
19:57
12/16/18
19:57
Upgrade
Stanley Black & Decker rating change at Deutsche Bank »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

, AET

Aetna

$0.00

(0.00%)

19:31
12/16/18
12/16
19:31
12/16/18
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

INCY

Incyte

$66.24

-1.04 (-1.55%)

AET

Aetna

$0.00

(0.00%)

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

HNT

Health Net

$0.00

(0.00%)

HUM

Humana

$300.41

-12.09 (-3.87%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

SNE

Sony

$51.32

-0.88 (-1.69%)

GOOG

Alphabet

$1,041.68

-21.44 (-2.02%)

GOOGL

Alphabet Class A

$1,050.62

-23.36 (-2.18%)

AAPL

Apple

$165.48

-5.45 (-3.19%)

BAC

Bank of America

$24.49

0.1 (0.41%)

BLK

BlackRock

$382.25

-5.29 (-1.37%)

CAT

Caterpillar

$126.78

0.79 (0.63%)

CVX

Chevron

$113.84

-2.15 (-1.85%)

DDAIF

Daimler AG

$0.00

(0.00%)

DAL

Delta Air Lines

$53.50

-0.03 (-0.06%)

ET

Energy Transfer LP

$14.08

-0.5 (-3.43%)

TOL

Toll Brothers

$32.23

-0.4 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 10

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 19

    Feb

  • 24

    Feb

  • 03

    Mar

EQT

EQT Corporation

$19.40

-0.78 (-3.87%)

18:54
12/16/18
12/16
18:54
12/16/18
18:54
Periodicals
EQT's board to seek meeting with Rice brothers, Reuters reports »

EQT Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

, EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

18:31
12/16/18
12/16
18:31
12/16/18
18:31
Downgrade
EQT Midstream Partners, EQGP Holdings rating change at Goldman Sachs »

EQT Midstream downgraded…

EQM

EQT Midstream Partners

$46.86

-0.1 (-0.21%)

EQGP

EQGP Holdings

$19.94

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEQP

Crestwood Equity

$32.29

0.47 (1.48%)

18:28
12/16/18
12/16
18:28
12/16/18
18:28
Upgrade
Crestwood Equity rating change at Goldman Sachs »

Crestwood Equity upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$66.24

-1.04 (-1.55%)

17:52
12/16/18
12/16
17:52
12/16/18
17:52
Hot Stocks
Innovent, Incyte announce agreement for three clinical-stage candidates in China »

Incyte and Innovent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

NSANY

Nissan

$0.00

(0.00%)

, RNLSY

Renault

$0.00

(0.00%)

17:14
12/16/18
12/16
17:14
12/16/18
17:14
Periodicals
Renault seeking Nissan shareholder meeting amid Ghosn crisis, Reuters says »

Renault (RNLSY) requested…

NSANY

Nissan

$0.00

(0.00%)

RNLSY

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

T

AT&T

$30.24

0.33 (1.10%)

, CMCSA

Comcast

$36.32

-0.43 (-1.17%)

16:48
12/16/18
12/16
16:48
12/16/18
16:48
Hot Stocks
Box Office Battle: 'Spider-Verse' wins weekend with $35M »

Sony's (SNE)…

T

AT&T

$30.24

0.33 (1.10%)

CMCSA

Comcast

$36.32

-0.43 (-1.17%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$51.32

-0.88 (-1.69%)

FOX

21st Century Fox

$48.79

-0.09 (-0.18%)

FOXA

21st Century Fox

$49.06

-0.07 (-0.14%)

LGF.A

Lionsgate

$15.59

-0.16 (-1.02%)

DIS

Disney

$112.21

-1.17 (-1.03%)

VIAB

Viacom

$28.56

-0.31 (-1.07%)

VIA

Viacom

$31.23

-0.4 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 20

    Mar

ELGX

Endologix

$0.71

0.0232 (3.39%)

16:17
12/16/18
12/16
16:17
12/16/18
16:17
Conference/Events
Endologix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPO

Precipio

$0.19

-0.0111 (-5.63%)

16:11
12/16/18
12/16
16:11
12/16/18
16:11
Conference/Events
Precipio to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSB

Mesabi Trust

$25.15

-1.1 (-4.19%)

16:08
12/16/18
12/16
16:08
12/16/18
16:08
Conference/Events
Mesabi Trust to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNT

Melinta Therapeutics

$1.19

-0.1 (-7.75%)

16:02
12/16/18
12/16
16:02
12/16/18
16:02
Conference/Events
Melinta Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$75.63

-1.32 (-1.72%)

15:55
12/16/18
12/16
15:55
12/16/18
15:55
Periodicals
Exxon Mobil shareholders call for greenhouse gas reduction targets, Reuters says »

A number of institutional…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$275.59

-4.93 (-1.76%)

, CNC

Centene

$127.55

-5.3 (-3.99%)

13:16
12/16/18
12/16
13:16
12/16/18
13:16
Periodicals
Health stocks preparing for market jolt after Obamacare ruling, Bloomberg says »

U.S. health-care stocks…

ANTM

Anthem

$275.59

-4.93 (-1.76%)

CNC

Centene

$127.55

-5.3 (-3.99%)

CI

Cigna

$205.34

-6.63 (-3.13%)

UNH

UnitedHealth

$265.06

-7.2 (-2.64%)

HUM

Humana

$300.41

-12.09 (-3.87%)

WCG

WellCare

$236.90

-7.44 (-3.04%)

MOH

Molina Healthcare

$131.72

-11.19 (-7.83%)

HNT

Health Net

$0.00

(0.00%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

  • 05

    Feb

  • 19

    Feb

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

13:02
12/16/18
12/16
13:02
12/16/18
13:02
Hot Stocks
Jeld-Wen announces final ruling in Steves & Sons litigation, to appeal decision »

Jeld-Wen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRA

Atara Biotherapeutics

$41.78

-0.74 (-1.74%)

12:55
12/16/18
12/16
12:55
12/16/18
12:55
Hot Stocks
Atara Biotherapeutics presents positive efficacy, safety results for EBV + LMS »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$133.95

2.595 (1.98%)

12:41
12/16/18
12/16
12:41
12/16/18
12:41
Hot Stocks
BeiGene announces updated Phase 1A/1B data on tislelizumab »

BeiGene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

Jeld-Wen

$14.27

-0.46 (-3.12%)

12:35
12/16/18
12/16
12:35
12/16/18
12:35
Hot Stocks
Jeld-Wen ordered to divest Pennsylvania plant to restore competition »

Federal Judge Robert…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

, RHHBY

Roche

$0.00

(0.00%)

04:55
12/16/18
12/16
04:55
12/16/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO Immuno-Oncology…

BMY

Bristol-Myers

$52.11

-1.54 (-2.87%)

RHHBY

Roche

$0.00

(0.00%)

CELG

Celgene

$68.20

-1.55 (-2.22%)

MRK

Merck

$76.50

-1.94 (-2.47%)

PFE

Pfizer

$43.84

-0.71 (-1.59%)

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

NEO

NeoGenomics

$13.25

-0.18 (-1.34%)

SGEN

Seattle Genetics

$60.46

-0.5 (-0.82%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

IMV

IMV Inc

$5.65

-0.14 (-2.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 29

    Dec

  • 11

    Jan

  • 11

    Jan

  • 24

    Jan

  • 16

    Feb

  • 18

    Mar

  • 20

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.